Neurocrine Biosciences, Inc.: Can The Gene Therapy Innovations Be A Growth Catalyst? 

Neurocrine Biosciences recently concluded its quarterly update, focusing on its strategic progress and financial achievements. One of the highlights is the significant year-over-year growth marked by the continued success of INGREZZA, its flagship product, which reported sales of $506 million for the quarter, reflecting over 20% annual growth. This consistent growth trajectory, despite seasonal payer dynamics, underscores the effective management and robust demand for INGREZZA in treating conditions like tardive dyskinesia (TD) and Huntington’s disease chorea.